Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461392 | 1.00 | KAT6A (0.51) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10912843 | 0.88 | ABL1 (0.42) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10562151 | 0.86 | KAT6A (0.40) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2107071 | 0.86 | NPC1 (0.58) | P2RX1 | |
| SCHEMBL690501 | 0.85 | KAT6A (0.54) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5866992 | 0.85 | MAPT (0.49) | KAT6A | |
| SCHEMBL27971413 | 0.84 | KAT6A (0.50) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| Benzoyl Chloride SCHEMBL8173899 | 0.84 | KAT6A (0.48) | KAT6AMGLLTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL11023974 | 0.84 | ALDH1A1 (0.43) | KAT6AMGLLHDAC8MRGPRX4 | |
| SCHEMBL29459930 | 0.84 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105826-A | HNO-releasable compound and preparation method thereof | 海南大学 | 2023-11-24 | — | — | CN | claimed |
| CN-117105897-A | HNO donor compound and preparation method thereof | 海南大学 | 2023-11-24 | — | — | CN | claimed |
| CN-114230495-B | Hydrogenated nitrosyl donor and preparation method thereof | 海南大学 | 2023-01-06 | — | — | CN | claimed |
| CN-114230495-A | Hydrogenated nitrosyl donor and preparation method thereof | 海南大学 | 2022-03-25 | — | — | CN | claimed |
| CN-114195731-A | Hydrogenated nitrosyl donor compound and preparation method thereof | 海南大学 | 2022-03-18 | — | — | CN | claimed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| CN-118221613-A | Substituted piperazine compound and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-06-21 | — | — | CN | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4037685-B9 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2024-03-06 | — | — | EP | disclosed |
| US-5221685-A | Insecticides, miticides or fungicides | UBE INDUSTRIES, LTD. (JP) | 1993-06-22 | — | — | US | disclosed |
| EP-0497367-A1 | Thiazoline derivatives, processes for their preparation and pesticidal compositions containing them | UBE INDUSTRIES, LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0124002-B1 | PROCESS FOR THE PREPARATION OF AROMATIC COMPOUNDS CONTAINING PERFLUORINATED SIDE CHAINS LINKED BY A HETEROATOM | BAYER AG (DE) | 1986-11-12 | — | — | EP | disclosed |
| US-4600787-A | Process for the preparation of aromatic compounds which contain perfluorinated side-chains bonded via a heteroatom | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0124002-A1 | Process for the preparation of aromatic compounds containing perfluorinated side chains linked by a heteroatom | BAYER AG (DE) | 1984-11-07 | — | — | EP | disclosed |
| US-4348395-A | 1,4-Dihydropyridazine compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| EP-0001439-B1 | 1-N-SUBSTITUTED 1.4-DIHYDROPYRIDAZINE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE FOR PHARMACEUTICALS | BAYER AG (DE) | 1981-01-28 | — | — | EP | disclosed |
| EP-0001439-A1 | 1-N-substituted 1.4-dihydropyridazine derivatives, method for their preparation and their use for pharmaceuticals | BAYER AG (DE) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | KAT6A 3520/4885MGLL 2015/4885TAS1R3 3383/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | KAT6A 3520/4885MGLL 2015/4885TAS1R3 3383/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | KAT6A 3520/4885MGLL 2015/4885TAS1R3 3383/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | KAT6A 3520/4885MGLL 2015/4885TAS1R3 3383/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KAT6A 3925/4885MGLL 2096/4885TAS1R3 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.